Objectives-Molecular biological testing for genetic diseases has grown rapidly, but speed, accuracy, specificity, sensitivity, throughput, and cost become more important as large scale screening is considered. This is a pilot study of an assay for the simultaneous detection of up to 31 cystic fibrosis mutations in a multicentre population based screening of 4476 Italian newborns. Conclusions-PCR/OLA is a robust, accurate, user friendly method for cystic fibrosis screening of newborns using blood spots in a semiautomated way at a low cost per mutation (0.8 Euro). (J Med Screen 1999;6:67-69) 
Cystic fibrosis is one of the most common severe recessive genetic disorders in the white population. Since the cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, more than 700 mutant alleles have been identified (CF Genetic Analysis Consortium: http://www.genet.sickkids.on.ca/ cftr/). In addition to F508, which accounts for a large proportion of mutant alleles in most populations, 1 there are 15-20 other mutations that comprise 2-15% of cystic fibrosis alleles, depending on the ethnic group studied (NIH Consensus Statement: Genetic Testing for Cystic Fibrosis, vol 15, no 4, April 14-16, 1997; http://text.nlm.nih.gov/tempfiles/is/temp BrPg58672.html). Therefore, in order to obtain a 95% confidence interval for detection of cystic fibrosis alleles, a large number of potential mutations must be screened. Nevertheless, several pilot screening initiatives have been performed. [2] [3] [4] [5] [6] [7] [8] [9] Most of these were based on analysis of only the most common CFTR mutation ( F508), 2 9 but a few included additional mutations. [6] [7] [8] In the latter, the major problem was the large number of mutated alleles that remained undetected by conventional genetic tests. In this report, we describe the results of a pilot study using an assay for the simultaneous detection of up to 31 cystic fibrosis mutations 10 11 in a population based screening of 4476 Italian newborns. The assay is based on the fluorescent oligonucleotide ligation technique, which has practical advantages over other strategies for multiple mutation detection. Briefly, the multiplex polymerase chain reaction (PCR), oligonucleotide ligation assay (PCR/OLA), sequence coded separation 10 11 is a non-isotopic semiautomated method for large scale multiplex analysis of multiple mutations within the CFTR gene. The fluorescent products of PCR/OLA are resolved electrophoretically from one another and from unligated probes under denaturing conditions using an Applied Biosystems sequencing system and analysis software. This procedure, combined with the use of a simple source of DNA such as Guthrie spots, limits handling of tubes and reagents. The procedure incorporates a multiplex amplification, followed by automated detection of fluorescently labelled products and semiautomated analysis of the results.
Materials and methods

INFORMED CONSENT
The purpose of the study was discussed in lay terms with both parents of the 4476 Italian newborns, including the risks and benefits for future family planning, and consent for participation was obtained. To ensure confidentiality, data obtained from this study were made available only to those conducting the research. Coded results were provided to clinical physicians at the respective centres for counselling purposes.
DNA PREPARATION A total of 4476 Guthrie spots were collected in the three participating centres from February 1997 to January 1998. Specifically, 1574 spots were collected in Turin (north western Italy), 1341 in Pavia (north central Italy), and 1561 in San Giovanni Rotondo (southern Italy). Blood spots were used as the source of DNA for PCR/OLA as follows: about 0.3 cm 2 of each was cut into smaller fragments and added to the extraction buVer supplied. After a 40 minute 97°C incubation in a thermal cycler, a brief high speed microcentrifugation was performed to separate the genomic DNA supernatant from the protein pellet. 10 PCR/OLA A 2.5 µl portion of the spot-containing solution was added to a new tube containing AmpliTaq Gold DNA Polymerase and multiplex PCR primers for "hot start" amplification of 15 regions of the CFTR gene, as suggested by the supplier (PE Biosystems, Foster City, CA, USA). Table 1 gives a list of mutations analysed. After amplification, an additional reagent which included the OLA probes and a thermostable ligase was added to the same tube, and the mixture was incubated for a few additional cycles to ligate the probes. Reaction products were then mixed with molecular mass standards, buVer, and formamide, heated, loaded on 8% (w/v) polyacrylamide gel (7 M urea), and analysed by either an Applied Biosystems model 373 or model 377 sequencing system. Genescan analysis software was used for preliminary data analysis, and its output imported into Genotyper software, which was then used for allele assignments at each of the 60 positions (both alleles for 31 mutations, with two sharing the same position; see table 1) and for preparation of a report on the data.
CONFIRMATORY TESTING All 144 carriers detected by PCR/OLA were confirmed by DNA sequencing on both strands using standard cycle sequencing methods and an Applied Biosystems sequencing system. Negative samples were confirmed at random using standard cycle sequencing methods. Table 2 gives a summary of the results. A total of 4476 Guthrie spots corresponding to an equivalent number of newborns in the three diVerent Italian centres were analysed using PCR/OLA. The number of carriers detected was 144, which translates into a carrier frequency of 1/31.1. Forty two carriers were detected from 1341 samples in Pavia (1/31.9), 53 from 1574 in Turin (1/29.7), and 49 from 1561 in San Giovanni Rotondo (1/31.8). All 144 carriers were confirmed by DNA sequence analysis of both strands. Neither homozygous nor compound heterozygous individuals were detected. In general, performance of the assay was very robust. There were occasional samples in which the amount of multiplex PCR product obtained was insuYcient to generate peak amplitudes that were within acceptable error tolerance for the assay. This problem was readily remedied by a new amplification of fresh aliquots of the blood spot.
Results
Fifteen diVerent mutations were detected (table 3), the most common being F508, which accounted for more than half of the total (90 of 144, 0.625). Other mutations found with greater than normal frequency were G542X, which is particularly common in southern Italy (14 of 49 individuals from San Giovanni Rotondo), N1303K (8 of 144), and R117H (8 of 144), which was detected only in the northern centres. Exon 21 T O  3 3  2  1  1  5  1  1  2  3  2  2  ---P V  2 7  --1  2  -1  -5  -1  2  1  1  SGR  30  14  2  1  1  1  ------- 
Discussion
Results of a pilot programme to detect CFTR carriers in a neonatal population using PCR/ OLA are presented. This approach facilitated detection of up to 31 diVerent CFTR alleles. The acceptance rate of this newborn testing was 100%. The observed carrier frequency for the 4476 individuals under study was 1/31.1. On the basis of this frequency, one individual in 3868 was expected to be either a homozygous mutant or a compound heterozygote for a CFTR mutant allele. No aVected individuals were detected. Although neither homozygous mutant nor compound heterozygous individuals were detected, the expected frequency of this event (1/3868) based on the calculated carrier frequency is not high enough to make the non-detection statistically significant, given the population size (4476). The prevalence of cystic fibrosis at birth in Italy has been estimated at 1/2700-1/2800 which corresponds to a carrier frequency of 1/26.5. 7 12 13 The discrepancy between this frequency and our results may be a function of the number of samples studied. However, two other factors may also have contributed. Firstly, our assay incorporates five additional mutations not included in the previous studies. Secondly, underestimation of the carrier frequency could result from not including individuals with cystic fibrosis associated diseases such as congenital bilateral absence of vas deferens, 14 chronic bronchiolectasis, 15 16 and pancreatitis. 17 As our study was carried out blind using Guthrie spots, such individuals would have been included. From a technical point of view, the study shows the eVectiveness and reliability of PCR/ OLA for carrier testing in the general population. The method, coupled with Guthrie spots as a source of DNA, proved to be user friendly and automatable, allowing high throughput analysis. Compared with existing methods, the overall cost per newborn tested, including reagents, supplies, and technician time, as well as the percentage of capital equipment cost and depreciation used for these samples, is significantly reduced. For the first time it has been possible to screen newborns in a semiautomated way at a low cost per mutation (0.8 Euro).
In conclusion, PCR/OLA has proved to be a robust, accurate, user friendly method for screening newborns for cystic fibrosis using blood spots. The addition of predominantly Mediterranean loci is under way and will further increase the utility of this assay in those countries. Furthermore, the test can be customised for screening for other genetic diseases in which examination of multiple mutations is desirable. The test can be easily implemented in clinics, providing information that is informative and easily interpreted by both doctor and patient.
